Extranodal sites of involvement in ALK+ and ALK− ALCL and PTCL-NOS
| Extranodal site . | ALK+, no. (%) . | ALK−, no. (%) . | PTCL-NOS, no. (%) . |
|---|---|---|---|
| Bone marrow | 10 (12) | 5 (7) | 72 (21)* |
| Peripheral blood (circulating tumor cells) | 2 (4) | 2 (3) | |
| Bone | 12 (14) | 5 (7) | 7 (2)* |
| Epidural | 2 (2) | 0 | 1 (.3) |
| Subcutaneous tissue | 9 (10) | 2 (3) | 21 (6) |
| Skin | 7 (8) | 12 (17) | 55 (16) |
| Liver | 3 (3) | 7 (10) | 39 (12) |
| Lung | 7 (8) | 9 (13) | 27 (8) |
| Spleen | 9 (10) | 2 (3) | 51 (15)* |
| Central nervous system | 1 (1) | 0 | 2 (.6) |
| Gastrointestinal | |||
| Stomach | 0 | 2 (3) | 10 (3) |
| Small intestine | 2 (2) | 2 (3) | 6 (2) |
| Large intestine | 0 | 0 | 5 (2) |
| Pleural effusion | 3 (3) | 4 (6) | 7 (2) |
| Pericardial effusion | 0 | 1 (1) | 1 (.3) |
| Ovary | 1 (1) | 0 | 0 |
| Breast | 1 (1) | 1 (1) | 1 (3) |
| Paranasal | 0 | 1 (1) | 3 (1) |
| Extranodal site . | ALK+, no. (%) . | ALK−, no. (%) . | PTCL-NOS, no. (%) . |
|---|---|---|---|
| Bone marrow | 10 (12) | 5 (7) | 72 (21)* |
| Peripheral blood (circulating tumor cells) | 2 (4) | 2 (3) | |
| Bone | 12 (14) | 5 (7) | 7 (2)* |
| Epidural | 2 (2) | 0 | 1 (.3) |
| Subcutaneous tissue | 9 (10) | 2 (3) | 21 (6) |
| Skin | 7 (8) | 12 (17) | 55 (16) |
| Liver | 3 (3) | 7 (10) | 39 (12) |
| Lung | 7 (8) | 9 (13) | 27 (8) |
| Spleen | 9 (10) | 2 (3) | 51 (15)* |
| Central nervous system | 1 (1) | 0 | 2 (.6) |
| Gastrointestinal | |||
| Stomach | 0 | 2 (3) | 10 (3) |
| Small intestine | 2 (2) | 2 (3) | 6 (2) |
| Large intestine | 0 | 0 | 5 (2) |
| Pleural effusion | 3 (3) | 4 (6) | 7 (2) |
| Pericardial effusion | 0 | 1 (1) | 1 (.3) |
| Ovary | 1 (1) | 0 | 0 |
| Breast | 1 (1) | 1 (1) | 1 (3) |
| Paranasal | 0 | 1 (1) | 3 (1) |
Statistical significance versus ALK− ALCL.